Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Preserved recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy

Yannic Bartsch, Caroline Atyeo, Jaewon Kang, Kathryn J Gray, Andrea G Edlow, Galit Alter
doi: https://doi.org/10.1101/2022.01.01.22268615
Yannic Bartsch
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Atyeo
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaewon Kang
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn J Gray
2Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea G Edlow
3Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galit Alter
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: galter@mgh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background SARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among pregnant women. Just as coordinated messaging from the CDC and leading obstetrics organizations began to increase vaccine confidence in this vulnerable group, the evolution of SARS-CoV-2 variants of concerns (VOC) including the Omicron VOC raised new concerns about vaccine efficacy, given their ability to escape vaccine-induced neutralizing antibodies. Early data point to a milder disease course following omicron VOC infection in vaccinated individuals. Thus, these data suggest that alternate vaccine induced immunity, beyond neutralization, may continue to attenuate omicron disease, such as antibody-Fc-mediated activity. However, whether vaccine induced antibodies raised in pregnancy continue to bind and leverage Fc-receptors remains unclear.

Methods VOC including Omicron receptor binding domain (RBD) or full Spike specific antibody isotype binding titers and FcγR binding were analyzed in pregnant women after the full dose regimen of either Pfizer/BioNtech BNT62b2 (n=10) or Moderna mRNA-1273 (n=10) vaccination using a multiplexing Luminex assay.

Findings Comparable, albeit reduced, isotype recognition was observed to the Omicron Spike and receptor binding domain (RBD) following both vaccines. Yet, despite the near complete loss of Fc-receptor binding to the Omicron RBD, Fc-receptor binding was largely preserved to the Omicron Spike.

Interpretation Reduced binding titer to the Omicron RBD aligns with observed loss of neutralizing activity. Despite the loss of neutralization, preserved Omicron Spike recognition and Fc-receptor binding potentially continues to attenuate disease severity in pregnant women.

Funding NIH and the Bill and Melinda Gates Foundation

Competing Interest Statement

G.A. is a founder and equity holder of Seromyx Systems, a company developing a platform technology that describes the antibody immune response. G.A. is an employee and equity holder of Leyden Labs, a company developing pandemic prevention therapeutics. G.A.s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors have declared that no conflicts of interest exist.

Funding Statement

This study was funded by the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, , 1U01CA260476-01, CIVIC75N93019C00052 and The Gates Foundation Global Health Vaccine Accelerator Platform (OPP1146996 and INV-001650). AGE received funding from the NIH (R01HD100022-S2) and March of Dimes Foundation (6-FY-20-223) to support sample collection.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Mass General Brigham Institutional Review Board (IRB protocol #2020P003538).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 02, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Preserved recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preserved recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy
Yannic Bartsch, Caroline Atyeo, Jaewon Kang, Kathryn J Gray, Andrea G Edlow, Galit Alter
medRxiv 2022.01.01.22268615; doi: https://doi.org/10.1101/2022.01.01.22268615
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Preserved recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy
Yannic Bartsch, Caroline Atyeo, Jaewon Kang, Kathryn J Gray, Andrea G Edlow, Galit Alter
medRxiv 2022.01.01.22268615; doi: https://doi.org/10.1101/2022.01.01.22268615

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2298)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11620)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2136)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (692)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (450)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)